StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
KSI.TO$5.45+0.55%
Fair $5.45+0.0%

KSI.TO

kneat.com, inc.

Healthcare / Health Information ServicesToronto

$5.45

+0.03 (+0.55%)

Fairly Valued+0.0%Fair Value $5.45Fund rank 31/100 · Data gapFallback financials|
SA 38/D
F-Score: 7/9
Low Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 33% · confianza 24%

FCF escenarios

weak_data · normalized FCF $-10.1M · quality 70.3/100

Data gap 31/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 40/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

38/100

D

Piotroski

7/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 1unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. ROE is -3.6%, below the 5% threshold
Thesis & Journal · KSI.TOLocal privado en este navegador · kneat.com, inc.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$524M

P/E

N/A

•

EV/EBITDA

32.6x

↑

ROE

-3.6%

↓

Gross Margin

75.8%

↑

Debt/Equity

0.44

↑
52-Week Range$5
$3$7

TradingView lightweight chart

KSI.TO price, volumen y niveles de valoración

Último $5.450Periodo +738.5%
Fair value: $5.450

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+38.6%

FCF CAGR

—

FCF margin

-15.4%

FCF / Net income

4.16x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $63.3M · net income $-2.3M · FCF $-9.8M

2022-FY → 2025-FY

Gross margin

75.8%+14.1% pts

Operating margin

-13.4%+27.8% pts

Net margin

-3.7%+34.8% pts

FCF margin

-15.4%+25.9% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$63.3M$63.3M$48.9M$34.2M$23.7M
Net Income$-2.3M$-2.3M$-7.7M$-14.5M$-9.1M
EBITDA$15.2M$15.2M$6.3M$-5.8M$-3.2M
EPS-0.02-0.02-0.09-0.19-0.12
Gross Margin75.8%75.8%75.1%67.6%61.7%
Operating Margin-13.4%-13.4%-12.2%-40.7%-41.2%
Net Margin-3.7%-3.7%-15.8%-42.4%-38.5%
Balance Sheet
Debt/Equity0.440.440.451.750.27
Current Ratio1.411.41———
Cash Flow
Free Cash Flow$-9.8M$-9.8M$-10.1M$-18.4M$-9.8M
Returns
ROE-3.6%-3.6%-11.9%-90.0%-35.2%
Valuation
EV/EBITDA32.6432.6478.15——
P/B7.967.967.9814.487.51
Growth & Yield
Revenue Growth29.3%29.3%43.0%44.1%—
EPS Growth77.8%77.8%52.6%-58.3%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -15.5%

Total return

-15.5%

Start / end P/E

n/dx → n/dx

EPS bridge

-0.09 → -0.02

Residual

-15.5%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term-15.5%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.